Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines

被引：0
|
作者：
Steffen Zopf
Matthias Ocker
Daniel Neureiter
Beate Alinger
Susanne Gahr
Markus F Neurath
Pietro Di Fazio
机构：
[1] University Hospital Erlangen,Department of Medicine 1
[2] Paracelsus Medical University,Institute of Pathology
[3] Klinikum Nuremberg Nord,Department of Pneumology
[4] Philipps University Marburg,Institute for Surgical Research
来源：
BMC Cancer | / 12卷
关键词：
DNA methyltransferase; Deacetylase inhibitor; Epigenetics; Transcriptional control; Hepatocellular carcinoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Ma, Brigette B. Y.
    Sung, Fion
    Tao, Qian
    Poon, Fan Fong
    Lui, Vivian W.
    Yeo, Winnie
    Chan, Stephen L.
    Chan, Anthony T. C.
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (02) : 107 - 114
  • [22] The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines
    Brigette B.Y. Ma
    Fion Sung
    Qian Tao
    Fan Fong Poon
    Vivian W. Lui
    Winnie Yeo
    Stephen L. Chan
    Anthony T.C. Chan
    Investigational New Drugs, 2010, 28 : 107 - 114
  • [23] Phase II study of oral panobinostat (LBH589), a potent pan-deacetylase inhibitor, in patients with refractory Cutaneous T-cell Lymphoma (CTCL)
    Duvic, M.
    Vanaclocha, F.
    Bernengo, M. G.
    Okada, C.
    Breneman, D.
    Zinzani, P. L.
    Zhang, L.
    Bopp, K.
    Laird, G.
    Hirawat, S.
    Prince, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell Carcinoma
    Hainsworth, John D.
    Infante, Jeffrey R.
    Spigel, David R.
    Arrowsmith, Edward R.
    Boccia, Ralph V.
    Burris, Howard A.
    CANCER INVESTIGATION, 2011, 29 (07) : 451 - 455
  • [25] Efficacy of Combining a Novel Histone Deacetylase Inhibitor with Radiotherapy in Hepatocellular Carcinoma through Inhibition of DNA Repair
    Cheng, J.
    Chou, C.
    Lu, Y.
    Teen, K.
    Cheng, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S650 - S650
  • [26] Synergistic Activity of Histone Deacetylase and Proteasome Inhibition Against Pancreatic and Hepatocellular Cancer Cell Lines
    Spratlin, J. L.
    Pitts, T. M.
    Kulikowski, G. N.
    Morelli, M. P.
    Tentler, J. J.
    Serkova, N. J.
    Eckhardt, S. G.
    ANTICANCER RESEARCH, 2011, 31 (04) : 1093 - 1103
  • [27] Effect of combined DNA methyltransferase and histone deacetylase inhibitors on hepatocellular carcinoma HepG2 cell line
    Sanaei, Masumeh
    Kavoosi, Fraidoon
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 40 : S53 - S53
  • [28] Efficacy of combining a novel histone deacetylase inhibitor with radiotherapy in human hepatocellular carcinoma through inhibition of DNA repair
    Cheng, Jason Chia-Hsien
    Chou, Chia-Hung
    Lu, Yen-Shen
    Hana, Ipih
    Hsu, Chan-Hsun
    Cheng, Ann-Lii
    Chen, Ching-Shih
    CANCER RESEARCH, 2009, 69
  • [29] Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report
    Gahr, Susanne
    Wissniowski, Till
    Zopf, Steffen
    Strobel, Deike
    Pustowka, Anette
    Ocker, Matthias
    JOURNAL OF CANCER, 2012, 3 : 158 - 165
  • [30] Suberoylanilide hydroxamic Acid, a histone deacetylase inhibitor, alters multiple signaling pathways in hepatocellular carcinoma cell lines
    Kunnimalaiyaan, Selvi
    Sokolowski, Kevin
    Gamblin, T. Clark
    Kunnimalaiyaan, Muthusamy
    AMERICAN JOURNAL OF SURGERY, 2017, 213 (04): : 645 - 651
12345